A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors - Trial NCT06384807
Access comprehensive clinical trial information for NCT06384807 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Pyramid Biosciences and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 170 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pyramid Biosciences
Timeline & Enrollment
Phase 1/2
Apr 01, 2024
Feb 01, 2028
Primary Outcome
Phase 1: Number of patients with adverse events (AEs),Phase 1: Recommended dose for expansion (RDE) and maximum tolerated dose (MTD),Phase 2: Objective Response Rate (ORR),Phase 2: Number of patients with AEs,Phase 2: Duration of Response (DoR)
Summary
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of PBI-410 in
 participants with previously treated, advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06384807
Non-Device Trial